Maravai Lifesciences Holdings, Inc. (MRVI) SEC Filing 8-K Material Event for the period ending Thursday, May 12, 2022

Maravai Lifesciences Holdings, Inc.

CIK: 1823239 Ticker: MRVI

View differences made from one to another to evaluate Maravai Lifesciences Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Maravai Lifesciences Holdings, Inc..


Assess how Maravai Lifesciences Holdings, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Maravai Lifesciences Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: MRVI
CIK: 1823239
Form Type: 8-K Corporate News
Accession Number: 0001823239-22-000020
Submitted to the SEC: Mon May 16 2022 4:33:57 PM EST
Accepted by the SEC: Mon May 16 2022
Period: Thursday, May 12, 2022
Industry: Pharmaceutical Preparations
  1. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: